A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

Summary

This open-label study will assess the effects of hepatic impairment on the pharmacokinetics of a single oral dose of aleglitazar in subjects with mild or moderate hepatic impairment (Child-Pugh class A or B) and in matched control subjects with normal hepatic function. Subjects will receive a single oral dose of aleglitazar, with assessment of the pharmacokinetics of aleglitazar on Days 1-5. Anticipated duration of study for each enrolled subject is approximately 6 weeks.

Timeline

Start

2010-09

Primary completion

2011-08

Completion

2011-08

Drugs

Indications

No indication recorded.